Countryfile Presenter to Host Awards

/in /by

Television presenter, Matt Baker, host of The One Show and Countryfile, has been announced as the host of the 2018 Ceva Animal Welfare Awards.

He will co-host the awards alongside the ceremony’s head judge, retired veterinary surgeon, Chris Laurence MBE FRCVS, who puts his name to the Vet of the Year Award.

TV presenter Matt Baker will host the Awards

Good Call Media has been recording video ‘teasers’ for the event and will also be there to record interviews with the winners on the night. The interviews will immediately be shared on social media outlets such as Ceva’s Facebook, Twitter, Linked In and You Tube channels

Click here to see the latest teaser.

Matt Baker said: “The countryside and love of animals are in my blood and I am passionate about improving animal welfare both in the UK and abroad. I applaud the Ceva Animal Welfare Awards for recognising both individuals and organisations who dedicate their lives to enhancing animal welfare and I look forward to personally acknowledging and thanking them for the work they do at the awards.”

Cuneyt Seckin, managing director of Ceva Animal Health, added: “We are thrilled to have Matt on board to help reward the crème de la crème of animal welfare professionals and organisations. We’re sure that his love of animals, the countryside and farming will make Matt a true asset to the awards.”

The Ceva Animal Welfare Awards will take place during a ceremony held in Birmingham ahead of BSAVA Congress on 4 April 2018. To find out more about the awards visit www.cevawelfareawards.com.

Volition Announce Trial Results

/in /by

The latest success for our client Volition, the multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers, are the interim results of a major trial – and, yet again, our cameras were there to record the event.

Click here to see the video report.

Cameron Reynolds: Volition CEO

The interim results from its first asymptomatic colorectal cancer (CRC) frontline screening study. This ongoing study is being carried out in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program. The interim results demonstrated that a small panel of three ELISA assays, when considered with the subjects’ ages and smoking histories, produced an area under the curve (AUC) of 83% and was able to detect 80% of Stage I CRC cases and 66% of High-Risk Adenomas (HRA) at 78% specificity, respectively.

Volition at the New York Stock Exchange

Good Call Media interviewed Cameron Reynolds, Chief Executive Officer of Volition, who commented, “After seven years of hard work, we are happy to announce these excellent early detection interim results from our ongoing front-line screening trial for colorectal cancer. Using only a small panel of three assays and considering certain limited patient variables, these data demonstrate that we can identify early stage and pre-cancerous adenomas at a high level of accuracy in an asymptomatic screening environment. Our tests use only a small amount of blood and could be added to routine blood screening regimens at a reasonable cost. We believe these are the first data to show high detection rates in a blood test, not only of early Stage I cancer, but also of the extremely important high-risk pre-cancerous adenomas. We believe that with further development, our Nu.QTM panel could form the basis of new CRC tests with early stage disease detection, and that our tests could become accessible to and usable by a wide section of the screening population around the world.”

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition’s website (http://www.volitionrx.com)

Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

 

 

 

Virtual Studio Proves A Hit

/in /by

Our virtual ‘news studio’ has been in demand again – this time to promote the prestigious World Veterinary Association Global Animal Welfare Awards.

Following the successful WVA Animal Welfare Awards 2017 WVA, our client, Ceva Sante Animale,  is supporting the 2nd WVA Animal Welfare Awards that will be presented during the World Veterinary Association Congress 2018 in Barcelona, Spain on 5th-8th May 2018.

Animal welfare will be celebrated at the event

Green Screen studio creates the feel of a real news programme

We have used our ‘green screen’ studio to create the feel of a mainstream TV news programme to publicise the Awards and also to give people important information on the timing, location and detail of the ceremony in Barcelona.

Click here to see the teaser video.

The aim of the WVA Animal Welfare Awards is to recognize and reward veterinarians who are contributing in their daily lives to the protection and welfare of animals and have provided outstanding and exemplary welfare-related services to animals, animal owners, fellow veterinarians and the public.

Good Call Media’s, Nik Wood, hosted the 2017 awards on stage in Incheon, South Korea. Our company also organised video reports highlighting the work of each of the winners in Colombia, the USA, Kenya, the Philippines, the UK and Egypt. The Awards will be staged as part of the World Veterinary Congress being staged in Barcelona between May 5-8, 2018. Nominations closed at the end of January and watch out for further studio-based trailers for the event in the coming months.

The Awards follow the success of the Ceva UK Welfare Awards which will also be staged again in 2018. That event will take place in Birmingham, UK, on 4 April and Good Call Media will be at the event to record interviews with the winners immediately they leave the stage. These interviews are then posted on social media within minutes of being recorded.

The speed and profile of this approach is particularly popular with the Awards sponsors as they too are interviewed and these clips, together with their company logos are included in the social media videos which they can then ‘share’ immediately after the ceremony finishes. “Because of our background working in BBC news and current affairs, we are able to turn video content around very quickly,” said Good Call Media’s Nik Wood.

Miami Location For Good Call Media

/in /by

Good Call Media is heading for Miami, Florida for its latest assignment.

We will be playing a key role in the New Technology Summit 2018 to be staged by our key client, Ceva Santé Animale, featuring a series of key opinion leaders, customers and Ceva personnel.

Nik Wood will host an on stage debate

Nik Wood will be hosting a major debate at the close of the event, which is being staged at the Hilton Downtown Miami between 20-22 March, 2018. We will also be filming the event and recording customer case study interviews with a series of clients and feeding regular video reports onto Ceva’s social media channels and internal news platforms. Ceva’s internal news service, Galaxy, regularly features news reports that we compile throughout the 44 different countries where the company operates.

The summit will cover latest hatchery solutions and performance challenges of tomorrow. Following on from the four previous New Technology & Vaccinology Summits, Ceva wants to give stakeholders the opportunity to exchange their views and experiences on some of the key topics, that the world’s poultry production has to face both today and tomorrow.

Ceva’s Poultry Franchise Director, Sylvain Comte said: “We would like this Summit to be a unique opportunity for you to share the latest information on the upcoming years’ antibiotic free and performance challenges in poultry production, from the perspective of primary breeders and large global production companies. A specific focus will be addressed to coccidiosis management through new vaccination solutions as part of the means to manage antibiotic free production and gut health from around the world. In addition to that, our talks will expose the most recent information and experiences on virus circulation and the added value of new technology vaccines to be launched in the North American & global markets.

Our Summit’s last day is dedicated to present recent hatchery solutions including equipment and quality recognition program that aim to ensure improved chick health. A large Experts Forum will take place at the end of the Summit in order to give you the opportunity to debate with key speakers, share experiences and enrich our common understanding on the discussed issues. Our ultimate goal is to help you to improve performance in your day-to-day activity, by providing you with the most advanced scientific and key practical information obtained in the field. We hope that you will enjoy meeting your fellow international poultry professionals and exchanging”.

XP Power Keeps Breaking Financial Records

/in /by

Our long standing client, XP Power continued breaking records with its latest full year financial results.

Click here to see our video report highlighting the company’s financial performance over the last 12 months when they recorded record order intake, revenues and earnings achieved during 2017.

The video was recorded in XP’s UK headquarters – we have been working with the business as it has grown dramatically in recent years, acquiring businesses in different regions including the US where we filmed XP’s impressive production facility.

James Peters, Chairman, commented:

“We are encouraged by the strong performance in 2017 and a good start to 2018. The Group entered 2018 with a strong order backlog and will also benefit from a full year’s trading from the acquired Comdel business which expands our addressable market.

Although we cannot be immune from all external economic shocks resulting from cyclicality in the capital equipment markets we serve, we are optimistic regarding our prospects for 2018.”

Good Call Media’s co-owner, Fiona Molloy, who manages our relationship with XP, said:”It’s great to be working in partnership with such a dynamic company and we have seen year on year growth throughout the years of our operations with XP.”

 

 

Volition’s Full Year Financial Results

/in /by

Our work with Volition RX continued with a video interview to mark the company’s full 2017 fiscal year financial results and a business update.

The report included a full length interview with Volition Chief Executive Officer, Cameron Reynolds. The company has also announced the results of clinical trials and that work will be highlighted in a second video that we have shot and edited.

Click here to connect to the financial video report.

He said: “I could not be more proud of our dedicated team at Volition.  During 2017, we, together with our collaborators, have made strong progress. After seven years of hard work, earlier this week we were excited to announce excellent early detection interim results from our ongoing front-line screening trial for colorectal cancer. We believe these are the first data to show high detection rates in a simple blood test, not only of early Stage I cancer, but also of the extremely important high-risk pre-cancerous adenomas. We believe that with further development, our Nu.QTM panel could form the basis of new colorectal cancer tests with early stage disease detection, and that our tests could become accessible to and usable by a wide section of the screening population around the world. The whole team will be working hard towards achieving our numerous milestones in 2018.”

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.